Skip to main content
VulnerabilityPublished

CVE-2026-123050: CIPCarbone Farmasimplex · Improper Certificate Validation

Affects CIPCarbone FarmasimplexSource CVE Database V5

0
Compare

Not known to be exploited · CVSS 7.1 High : upgrade to 16.2.0 soon.

Data as of 17 Nov 2026, 14:37 UTC

CVSS 4.0 base score
7.1High
How severe the flaw is on the 0–10 CVSS scale.

Thin evidence

One scorer or none
CVSS scores by source
CNA (ENISA)CVSS 4.07.1
Patch
Available – fixed in 16.2.0
CVSS:4.0/AV:N/AC:H/AT:N/PR:N/UI:N/VC:H/VI:H/VA:L/SC:N/SI:N/SA:N/E:U

Exploitation evidence

  1. Disclosed: evidence found.

    CVE published 17 Nov 2026

  2. Detectable: no evidence on record.

    No public nuclei template indexed

  3. Weaponized: no evidence on record.

    No public exploit code indexed in Metasploit or Exploit-DB

  4. Exploited in the wild: no evidence on record.

    Not in CISA KEV and no source reports exploitation

  5. Observed by OffSeq Mirage: no evidence on record.

    No attack traffic recorded by OffSeq Mirage sensors

A missing step is not evidence of safety. Sources: cve.org (opens in a new tab), the Metasploit, Exploit-DB and nuclei-templates index as of 16 Nov 2026.

What to do

Upgrade CIPCarbone Farmasimplex to 16.2.0.

Affected software

ProductAffectedFixed in
CIPCarboneFarmasimplexAffected
  • <16.2.0
Fixed in
  • 16.2.0

AI-suggested

Upgrade affected Farmasimplex modules to version 16.2.0 or later, where the improper certificate validation vulnerability has been fixed. No other vendor advisories indicate alternative mitigations or that no action is required.

Description

CIPCarbone Farmasimplex healthcare integration modules before version 16.2.0 improperly validate TLS certificates. This flaw allows attackers who can intercept network traffic to impersonate trusted healthcare services, enabling man-in-the-middle attacks that may disclose or modify sensitive data. The vulnerability is addressed in version 16.2.0.

References

Community reviews

Loading reviews…